BMP-7 protects mesangial cells from injury by polymeric IgA

Kidney International

Volumn 74, Issue 8, 2008, Pages 1026-1039

  Chan, Wai Long ^a   Leung, Joseph C K ^a   Chan, Loretta Y Y ^a   Tam, K Y ^a   Tang, Sydney C W ^a   Lai, Kar Neng ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

BMP 7; IgAN; PPAR ; Smad6; Smad7; TNF

Indexed keywords

FIBRONECTIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; OSTEOGENIC PROTEIN 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; ROSIGLITAZONE; SECRETORY COMPONENT; SMAD2 PROTEIN; SMAD3 PROTEIN; SMAD6 PROTEIN; SMAD7 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CELL CULTURE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOGLOBULIN A NEPHROPATHY; MALE; MESANGIUM CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; PROTEIN SYNTHESIS;

BONE MORPHOGENETIC PROTEIN 7; CELLS, CULTURED; FEMALE; GLOMERULONEPHRITIS, IGA; HUMANS; IMMUNOGLOBULIN A; MALE; MESANGIAL CELLS; PPAR GAMMA; SMAD PROTEINS; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR-ALPHA;

EID: 53049094210     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2008.209     Document Type: Article

References (51)

1. D'Amico G. The commonest glomerulonephritis in the world: IgA nephropathy. Q J Med 1987; 64: 709-727.
2. Julian BA, Tomana M, Novak J et al. Progress in the pathogenesis of IgA nephropathy. Adv Nephrol Necker Hosp 1999; 29: 53-72.
3. Lai KN, Tang SC, Guh JY et al. Polymeric IgA1 from patients with IgA nephropathy upregulates transforming growth factor-beta synthesis and signal transduction in human mesangial cells via the rennin-angiotensin system. J Am Soc Nephrol 2003; 14: 3127-3137.
4. Leung JC, Tang SC, Chan LY et al. Polymeric IgA increases the synthesis of macrophage migration inhibitory factor by human mesangial cells in IgA nephropathy. Nephrol Dial Transplant 2003; 18: 36-45.
5. Helder MN, Ozkaynak E, Sampath KT et al. Expression pattern of osteogenic protein-1 (bone morphogenetic protein-7) in human and mouse development. J Histochem Cytochem 1995; 43: 1035-1044.
6. Kopp JB. BMP receptors in kidney. Kidney Int 2000; 58: 2237-2238.
7. Ebara S, Nakayama K. Mechanism for the action of bone morphogenetic proteins and regulation of their activity. Spine 2002; 27: S10-S15.
8. Klahr S, Morrissey J. Obstructive nephropathy and renal fibrosis: the role of bone morphogenic protein-7 and hepatocyte growth factor. Kidney Int Suppl 2003; 64: S105-S112.
9. Vukicevic S, Basic V, Rogic D et al. Osteogenic protein-1 (bone morphogenetic protein-7) reduces severity of injury after ischemic acute renal failure in rat. J Clin Invest 1998; 102: 202-214.
10. Wang SN, Lapage J, Hirschberg R. Loss of tubular bone morphogenetic protein-7 in diabetic nephropathy. J Am Soc Nephrol 2001; 12: 2392-2399.
11. Zeisberg M, Bottiglio C, Kumar N et al. Bone morphogenic protein-7 inhibits progression of chronic renal fibrosis associated with two genetic mouse models. Am J Physiol Renal Physiol 2003; 285: F1060-F1067.
12. Wang S, Hirschberg R. BMP7 antagonizes TGF-beta -dependent fibrogenesis in mesangial cells. Am J Physiol Renal Physiol 2003; 284: F1006-F1013.
13. Gould SE, Day M, Jones SS et al. BMP-7 regulates chemokine, cytokine, and hemodynamic gene expression in proximal tubule cells. Kidney Int 2002; 61: 51-60.
14. Wang S, Chen Q, Simon TC et al. Bone morphogenic protein-7 (BMP-7), a novel therapy for diabetic nephropathy. Kidney Int 2003; 63: 2037-2049.
15. Vukicevic S, Latin V, Chen P et al. Localization of osteogenic protein-1 (bone morphogenetic protein-7) during human embryonic development: high affinity binding to basement membranes. Biochem Biophys Res Commun 1994; 198: 693-700.
16. Zeisberg M. Bone morphogenic protein-7 and the kidney: current concepts and open questions. Nephrol Dial Transplant 2006; 21: 568-573.
17. Miyazaki Y, Ueda H, Yokoo T et al. Inhibition of endogenous BMP in the glomerulus leads to mesangial matrix expansion. Biochem Biophys Res Commun 2006; 340: 681-688.
18. Sugimoto H, Grahovac G, Zeisberg M et al. Renal fibrosis and glomerulosclerosis in a new mouse model of diabetic nephropathy and its regression by bone morphogenic protein-7 and advanced glycation end product inhibitors. Diabetes 2007; 56: 1825-1833.
19. Chan LY, Leung JC, Tsang AW et al. Activation of tubular epithelial cells by mesangial-derived TNF-alpha: glomerulotubular communication in IgA nephropathy. Kidney Int 2005; 67: 602-612.
20. Vassalli P. The pathophysiology of tumor necrosis factors. Annu Rev Immunol 1992; 10: 411-452.
21. Feldmann M, Brennan FM, Maini R. Cytokines in autoimmune disorders. Int Rev Immunol 1998; 17: 217-228.
22. Ruddle NH. Tumor necrosis factor (TNF-alpha) and lymphotoxin (TNF-beta). Curr Opin Immunol 1992; 4: 327-332.
23. Lee MJ, Yang CW, Jin DC et al. Bone morphogenetic protein-7 inhibits constitutive and interleukin-1 beta-induced monocyte chemoattractant protein-1 expression in human mesangial cells: role for JNK/AP-1 pathway. J Immunol 2003; 170: 2557-2563.
24. Evans RM. The steroid and thyroid hormone receptor superfamily. Science 1988; 240: 889-895.
25. Lebovitz HE, Dole JF, Patwardhan R et al. Rosiglitazone monotherapy is effective in patients with type 2 diabetes. J Clin Endocrinol Metab 2001; 86: 280-288.
26. Poynter ME, Daynes RA. Peroxisome proliferator-activated receptor alpha activation modulates cellular redox status, represses nuclear factor-kappaB signaling, and reduces inflammatory cytokine production in aging. J Biol Chem 1998; 273: 32833-32841.
27. Lee S, Kim W, Kang KP et al. Agonist of peroxisome proliferator-activated receptor-gamma, rosiglitazone, reduces renal injury and dysfunction in a murine sepsis model. Nephrol Dial Transplant 2005; 20: 1057-1065.
28. Sivarajah A, Chatterjee PK, Patel NS et al. Agonists of peroxisome-proliferator activated receptor-gamma reduce renal ischemia/reperfusion injury. Am J Nephrol 2003; 23: 267-276.
29. Ghosh SS, Gehr TW, Ghosh S et al. PPARgamma ligand attenuates PDGF-induced mesangial cell proliferation: role of MAP kinase. Kidney Int 2003; 64: 52-62.
30. McCarthy KJ, Routh RE, Shaw W et al. Troglitazone halts diabetic glomerulosclerosis by blockade of mesangial expansion. Kidney Int 2000; 58: 2341-2350.
31. Miyazono K, Maeda S, Imamura T. BMP receptor signaling: transcriptional targets, regulation of signals, and signaling cross-talk. Cytokine Growth Factor Rev 2005; 16: 251-263.
32. Hruska KA, Mathew S, Saab G. Bone morphogenetic proteins in vascular calcification. Circ Res 2005; 97: 105-114.
33. Wang S, Hirschberg R. Bone morphogenetic protein-7 signals opposing transforming growth factor beta in mesangial cells. J Biol Chem 2004; 279: 23200-23206.
34. Wetzel P, Haag J, Campean V et al. Bone morphogenetic protein-7 expression and activity in the human adult normal kidney is predominantly localized to the distal nephron. Kidney Int 2006; 70: 717-723.
35. Ventura JJ, Kennedy NJ, Flavell RA et al. JNK regulates autocrine expression of TGF-beta1. Mol Cell 2004; 15: 269-278.
36. Schrum LW, Bird MA, Salcher O et al. Autocrine expression of activated transforming growth factor-beta(1) induces apoptosis in normal rat liver. Am J Physiol Gastrointest Liver Physiol 2001; 280: G139-G148.
37. Kim SJ, Angel P, Lafyatis R et al. Autoinduction of transforming growth factor beta 1 is mediated by the AP-1 complex. Mol Cell Biol 1990; 10: 1492-1497.
38. Wong C, Rougier-Chapman EM, Frederick JP et al. Smad3-Smad4 and AP-1 complexes synergize in transcriptional activation of the c-Jun promoter by transforming growth factor beta. Mol Cell Biol 1999; 19: 1821-1830.
39. Zhang M, Fraser D, Phillips A. ERK, p38, and Smad signaling pathways differentially regulate transforming growth factor-beta1 autoinduction in proximal tubular epithelial cells. Am J Pathol 2006; 169: 1282-1293.
40. Imamura T, Takase M, Nishihara A et al. Smad6 inhibits signalling by the TGF-beta superfamily. Nature 1997; 389: 622-626.
41. Nakao A, Afrakhte M, Moren A et al. Identification of Smad7, a TGFbeta-inducible antagonist of TGF-beta signalling. Nature 1997; 389: 631-635.
42. Itoh F, Asao H, Sugamura K et al. Promoting bone morphogenetic protein signaling through negative regulation of inhibitory Smads. EMBO J 2001; 20: 4132-4142.
43. Chan LY, Leung JC, Tang SC et al. Tubular expression of angiotensin II receptors and their regulation in IgA nephropathy. J Am Soc Nephrol 2005; 16: 2306-2317.
44. Hostetter TH, Rosenberg ME, Ibrahim HN et al. Aldosterone in progressive renal disease. Semin Nephrol 2001; 21: 573-579.
45. Sun GP, Kohno M, Guo P et al. Involvements of Rho-kinase and TGF-beta pathways in aldosterone-induced renal injury. J Am Soc Nephrol 2006; 17: 2193-2201.
46. Terada Y, Kobayashi T, Kuwana H et al. Aldosterone stimulates proliferation of mesangial cells by activating mitogen-activated protein kinase 1/2, cyclin D1, and cyclin A. J Am Soc Nephrol 2005; 16: 2296-2305.
47. Quinkler M, Zehnder D, Eardley KS et al. Increased expression of mineralocorticoid effector mechanisms in kidney biopsies of patients with heavy proteinuria. Circulation 2005; 112: 1435-1443.
48. Onozato ML, Tojo A, Kobayashi N et al. Dual blockade of aldosterone and angiotensin II additively suppresses TGF-beta and NADPH oxidase in the hypertensive kidney. Nephrol Dial Transplant 2007; 22: 1314-1322.
49. Ichijo T, Voutetakis A, Cotrim AP et al. The Smad6-histone deacetylase 3 complex silences the transcriptional activity of the glucocorticoid receptor: potential clinical implications. J Biol Chem 2005; 280: 42067-42077.
50. Leung JC, Tang SC, Lam MF et al. Charge-dependent binding of polymeric IgA1 to human mesangial cells in IgA nephropathy. Kidney Int 2001; 59: 277-285.
51. Leung JC, Tsang AW, Chan DT et al. Absence of CD89, polymeric immunoglobulin receptor, and asialoglycoprotein receptor on human mesangial cells. J Am Soc Nephrol 2000; 11: 241-249.